Risk Factors for the Recurrence of Benign Paroxysmal Positional Vertigo: A Systematic Review and Meta-Analysis

Shichang Li, MD¹, Zijing Wang, MD¹, Yan Liu, MD¹, Jie Cao, MD¹, Hongwei Zheng, MD¹, Yuanyuan Jing, MD¹, Lin Han, MD¹, Xin Ma, MD¹, Ruiming Xia, MD¹, and Lisheng Yu, MD¹

Abstract
Objective: Benign paroxysmal positional vertigo (BPPV) has a high recurrence rate, but the risk factor–associated recurrence are elusive. Methods: Searches were performed in PubMed, Embase, Cochrane library, Web of science, Chinese National Knowledge Infrastructure, and Sino Med up to November 3, 2019. The effect size was analyzed by odds ratio and 95% CI. Data from eligible studies were meta-analyzed using Stata version 15.0. Results: Our search resulted in a total of 4076 hits. Twenty-four outcomes of sixty articles were included in the meta-analysis. Risk factors for the recurrence of BPPV included female gender, age (≥65 years), hyperlipidemia, diabetes, hypertension, migraine, cervical spondylosis, osteopenia/osteoporosis, head trauma, otitis media, abnormal vestibular evoked myogenic potential, and long use of computers. No significant differences were found in side, type of the involved semicircular canals, smoking, alcohol consumption, stroke, ear surgery, duration of vertigo before treatment, the times of repositioning, Meniere disease, sleep disorders, hypercholesterolemia, and 25-hydroxy vitamin D. Conclusion: These findings strengthen clinical awareness of early warning to identify patients with potential relapse risk of BPPV and clinicians should counsel patients regarding the importance of follow-up after diagnosis of BPPV.

Keywords
benign paroxysmal positional vertigo, recurrence, risk factors, meta-analysis

Introduction
Benign paroxysmal positional vertigo (BPPV), first described by Bárány,¹ is the most common cause of vertigo.² The definite etiology of BPPV is still unclear. It was reported that advanced age, head trauma, inactivity, viral labyrinthitis, and ischemia of the anterior vestibular artery may dispose individuals to BPPV.³ The major pathophysiological process in BPPV involves displaced ototonia from the macula of the utricular otolith which drop in the semicircular canals. When the position of the head changes relative to the direction of gravity, the otoletic debris will move to a new position within the semicircular canals, causing a false sense of rotation.⁴ Typical BPPV manifests as recurring transient positional-related vertigo and torsional or horizontal nystagmus on provocative head motion. Nearly 94% of BPPV cases affects the posterior semicircular canals (PSCs),⁵ while the horizontal semicircular canal is the next most common.⁶ The diagnosis of BPPV depends on the patient’s history and the characteristics of nystagmus on positional testing. In many cases, BPPV settles spontaneously within a few weeks. It was revealed that more than 95% of cases can be cured by canalith repositioning therapy (CRT).⁷ Although BPPV generally responds well to CRT, there is a high recurrence rate after the initial resolution.⁸ It was reported that 10% to 18% patients relapse during a 1-year follow-up period.⁹ Brandt suggested that relapse rate can be as high as 50% in 10 years and in addition, most recurrences are observed during the first year after the CRM.¹⁰ Several studies have demonstrated
that age,\textsuperscript{11} family history,\textsuperscript{12} diabetes and hypertension,\textsuperscript{13} comorbidities,\textsuperscript{14} delayed BPPV treatment using CRT,\textsuperscript{11} multiple canal involvement,\textsuperscript{15} endolymphatic hydrops,\textsuperscript{16} bone mineral density (BMD), and serum vitamin D levels\textsuperscript{17,18} may be associated with the recurrence of BPPV. However, the results are conflicting. Thus, in this study, we try to identify the factors associated with recurrent BPPV.

**Methods**

We carried out a systematic review and meta-analysis to test the association between potential risk factors and recurrent BPPV along with a protocol developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).

**Literature Search**

A systematic literature search of PubMed, the Cochrane Library, Web of Science, Embase, Chinese National Knowledge Infrastructure (CNKI) and Sino Med was conducted to identify relevant studies published from database inception until November 3, 2019. The search strategy is detailed in Supplementary 1. All considered studies were imported into a reference management software (Endnote X 8·0·0) and duplicate publications were deleted.

**Study Selection**

All search results were reviewed by the lead author (Li) who read study titles to remove any clearly nonrelevant articles based on the inclusion and exclusion criteria listed below. The remaining abstracts were read and judged as possibly relevant based on inclusion and exclusion criteria. All studies deemed to be possibly relevant were read in full and independently judged against inclusion and exclusion criteria. All studies deemed to be possibly relevant were read in full and independently judged against inclusion and exclusion criteria of the individual phase by 2 reviewers (Li and Wang). Disputes were resolved by consensus and consultation when necessary with a third reviewer (Zheng). Hand searches of the references from all the included studies were conducted to identify studies missed in the bibliographic searches.

**Inclusion and Exclusion Criteria**

Studies were included if they satisfied the following PICO(S) (participant, intervention, comparator, outcome [study design]) criteria:

1. Participant: adults aged 18 years and older, and BPPV were diagnosed according to guideline.\textsuperscript{19}
2. Intervention: assessment of the risk factors of BPPV patients and recurrent BPPV patients, for example, gender, age, the affected side, smoking, alcohol, hyperlipidemia, diabetes mellitus, hypertension, migraine, cervical spondylosis, complication, osteopenia/osteoporosis, ischemic heart disease, and so on.
3. Comparator: comparison groups of recurrence and non-recurrence.
4. Outcome: Recurrence of BPPV was used as an outcome data on the risk factors for recurrence of BPPV reported as odds ratios (ORs) with 95% CI or equivalent.
5. Study design: observational studies including cohort, case–control, or cross-sectional studies.

Studies were excluded if the following criteria were met:

(a) If they lacked a control group or if they were reviews, theoretical research, systematic reviews and/or meta-analysis, conference reports, expert comments, or economic analysis and case reports.
(b) Chapters from a book
(c) Duplication of results
(d) Studies with too little information or unclear data description
(e) Animal studies

**Data Extraction**

Two reviewers (Li and Wang) independently selected studies on the basis of inclusion and exclusion criteria. Disparities in selection were resolved through discussion and ultimately by a third reviewer (Zheng). Studies were initially reviewed on the basis of title and abstract, and those deemed relevant were reviewed in full text to establish the final set of studies ultimately included. From these studies, data were abstracted in duplicate (by Li and Wang) to verify the accuracy. The following data were independently extracted by 2 researchers: first author, year of publication, location of study, type of study design, population size (recurrence/non-recurrence), sample ages, follow-up time, risk factors, and other relevant information. We also contacted the authors about unclear or missing information when necessary.

**Quality Assessment**

Risk of bias assessment was analyzed for each article by 2 investigators (Li and Wang) using the Newcastle-Ottawa Scale (NOS),\textsuperscript{20} which is a scale for quality assessment of nonrandomized studies in meta-analyses, and disagreement was resolved by discussion. The NOS is based on an accumulative score in each of 3 categories: selection, comparability, and exposure or outcome. The NOS scores range between 0 and 9 stars. Studies with 6 to 9 stars were considered to be at high risk of bias (ROB), studies with 4 to 5 stars were considered to be at medium ROB, and studies with 1 to 3 stars were considered to be at high ROB. Detailed results of the NOS quality appraisal are summarized in Table 1.

**Statistical Analysis**

Studies evaluating the risk factors for recurrent BPPV were included in a meta-analysis if relevant outcomes were reported in at least 2 articles. Dichotomous data were summarized using OR and 95% CI. Continuous data were summarized using mean difference (MD) and 95% CI. Statistical significance was set at
| Author (country), year | Study design | Sample size | Recurrence definition | Follow-up time | Identified risk factors | NOS |
|------------------------|--------------|-------------|-----------------------|----------------|------------------------|-----|
| Sunami et al, 2005     | Case-control | 122         | Positive Dix-Hallpike test | Mean 8.7 months | Age, smoking habit and alcohol consumption, canal paresis (CP) on caloric test, type of BPPV, and duration of BPPV | 5   |
| JY Park and DS Jeong, 2011 | Case-control | 87          | Is there a recurrence during telephone follow-up | Mean 24 months | Age, sex, and days prior to visit, side | 6   |
| Wang et al, 2015       | Case-control | 118         | Positive test of relocation after cure | Mean 24 months | Age, gender, semicircular canal involvement, precipitating factors, time of recurrence, magnetic resonance imaging of the head, hypertension, diabetes mellitus, hyperlipidemia, posterior circulation ischemia, and obstructive sleep apnea-hypopnea syndrome (OSAHS) | 7   |
| Liu XH et al, 2013     | Case-control | 109         | Is there a recurrence during telephone follow-up | Mean 24 months | Age, family history, migraine history, intracranial arterial carotid stenosis, and stroke history | 6   |
| Do et al, 2011         | Case-control | 138         | Reappearance of a similar whirling dizziness or reappearance of a similar rotating nystagmus. | 8-14 months | Age, gender, affected semicircular canal, average symptom duration (hour) | 8   |
| Brandt et al, 2006     | Cohort       | 125         | A self-evaluating questionnaire about the monthly recurrence rate within the first year and in each subsequent year | Mean 10 months | Gender, age, the number of recurrences, migraine, affected ear, and cause of BPPV | 7   |
| Su-Jin Han et al, 2019 | Cohort       | 21355       | Whirling dizziness disappearing for at least 1 month from the initial diagnosis and then recurring | ≥12 months | Age, sex, vestibular disease, headache, osteoporosis, hypertension, diabetes, kidney disease, connective tissue invasion autoimmune disease, cerebrovascular disease, and ischemic heart disease | 8   |
| Ahn et al, 2013        | Case-control | 144         | All patients were instructed to return if vertigo redeveloped | Mean 32 months | Traumatic brain injury | 6   |
| Rhim (Korea), 2016     | Cohort       | 295         | Recurrence was defined as the recurrence of BPPV that occurred 1 month after cure | Mean 26 months | Age, sex, and visit of treatment sessions in initial episode | 7   |
| Zhou et al, 2015       | Case-control | 59          | Definition of relapse not stated | / | Vestibular evoked myogenic potential (VEMP) | 5   |
| Zhang et al, 2012      | Case-control | 185         | Recurrence was defined as the recurrence of BPPV that occurred 72 hours after cure | Mean 13 months | Hyperlipidemia, hypertension, and diabetes | 6   |
| Yeo et al, 2018        | Case-control | 370         | / | 1 year | Gender, numbers of CRM for successful treatment, and affected semicircular canal | 5   |
| Yang et al, 2017       | Case-control | 130         | A relapse of vertigo that occurred 1 or more months after successful CRP at our clinic or two or more treatments for BPPV in other clinics during the preceding year. | ≥1 month | Bone mineral density (BMD) and 25-hydroxyvitamin D | 7   |
| Yamamoto et al, 2013   | Case-control | 63          | / | / | Traumatic brain injury | 4   |
| Wei et al, 2018        | Cohort       | 127         | / | 6 months | Age, gender, hypertension, diabetes and hyperlipidemia, hypercholesterolemia, migraine, and cervical spondylitis | 5   |
| Wang et al, 2018       | Case-control | 67          | Recurrence was considered if the clinical manifestation of positional vertigo and nystagmus developed after at least a 2-week symptom-free interval following previous successful treatments, and the semicircular canal on the same side was involved as confirmed by standard test. | 24 months | Age, gender, smoking, alcohol consumption and complications, hypertension, diabetes and hyperlipidemia, serum homocysteine, serum folic acid, and Pittsburgh Sleep Quality Index (PSQI) scale | 6   |
| Tirelli et al, 2017    | Case-control | 178         | Patients were individually contacted by the department staff to question them about possible BPPV relapses | 1-6 years | Whether repeated CRP in patients with post-CRP dizziness | 7   |
| Tian et al, 2018       | Case-control | 201         | Recurrence was defined as the recurrence of BPPV that occurred ≥1 month after cure | 3 years | Gender, age, hypertension, diabetes, and hyperlipidemia | 7   |
| Tanimoto et al, 2008   | Case-control | 145         | Recurrent BPPV was diagnosed on the basis of typical history and nystagmus and included BPPV occurring in both the same ear and the other ear. | 1 year | Gender, age, osteoporosis, and head trauma | 8   |
| Talaat et al, 2016     | Case-control | 93          | Patients were instructed to return to the clinic immediately if they suspected BPPV recurrence. | 18 months | Vitamin D deficiency | 6   |
| Talaat et al, 2015     | Case-control | 80          | Recurrence was defined as BPPV that occurred after 1-month or more of a successful reposition maneuver, or patients with confirmed attack(s) of BPPV that was successfully treated during the preceding year as indicated by the medical records. | 12 months | Bone mineral density (BMD) and vitamin D deficiency | 7   |

(continued)
| Author (country), year | Study design | Sample size | Recurrence definition | Follow-up time | Identified risk factors | NOS |
|------------------------|--------------|-------------|-----------------------|----------------|------------------------|-----|
| Suarez et al (Uruguay), 2011 | Case-control | 376 | Positional vertigo and nystagmus that disappeared after repositioning maneuvers (Epley maneuver) but in a period from 7 days to 4 months had a recurrence of positional vertigo and nystagmus, by canalithiasis in the same ear as the previous presentation. | ≥12 months | Mild head trauma and idiopathic etiology | 8 |
| Su et al (China), 2016 | Cohort | 243 | The recurrence of BPPV is clinically defined as the detection of vertigo evoked by changing position 3 months after successful treatment with Epley maneuver. | ≥12 months | The number of episodes of, the number of times Epley maneuver was performed, age, sex, hypertension, hyperlipidemia, diabetes, head trauma, and Meniere disease | 8 |
| Sreenivas et al (India), 2019 | Case-control | 71 | / | 6-12 months | Hypertension, diabetes, hypothyroidism, hypothyroid, vitamin D levels, ipsilateral sensorimotor hearing loss, and hyper cholesterol | 5 |
| Sayal et al (USA), 2019 | Case-control | 111 | / | / | Using an electric toothbrush | 5 |
| Sakaida et al (Japan), 2003 | Case–control | 50 | A recurrence of positionally provoked vertigo | Mean 60 months | Affected semicircular canal, sex, and age | 6 |
| Rhim et al (Korea), 2019 | Case-control | 332 | Direct telephone calls to patients were made to ensure the accuracy of the recurrence data. | 12 months | Sex, age, types and locations of semicircular canals, diabetes, hypertension, hyperlipidemia, and vitamin D concentrations | 6 |
| Pollak et al (Israel), 2006 | Case-control | 232 | Recurrence was considered as the reappearance of symptoms and signs after a symptom-free interval of more than 1 month following successful treatment. | Mean 17.6 months | Bilateral or unilateral benign paroxysmal positioning vertigo | 5 |
| Pollak et al (Israel), 2005 | Case-control | 53 | Recurrence was defined as reappearance of symptoms and signs of BPPV of any subtypes at least one month apart from the initial horizontal BPPV attack. | Mean 97 months | Gender, age, BPPV subtype, duration of symptoms prior to diagnosis, time | 7 |
| Picciotti et al (Italy), 2016 | Case-control | 475 | Patients with a reappearance of positional nystagmus after at least 2 weeks from its resolution | Mean 30 months | Age, sex, semicircular canal affected, cranial trauma | 7 |
| Nunez et al (Israel), 2000 | Case-control | 151 | All patients were invited to contact us if they had recurrence of position-induced vertigo in the future. | Mean 26 months | Sex, age, duration of symptoms, presumed cause, or treating physician | 6 |
| Maslovar et al (Croatia), 2018 | Case-control | 31 | The criteria for recurrence are recurrence of symptoms and a positive Dix-Hallpike test after successfully implemented Epley repositioning maneuvers. | Mean 6 months | Age, sex, and vitamin D levels | 6 |
| Martellucci et al (Italy), 2019 | Case-control | 47 | If the Dix-Hallpike test was positive for a PC-BPPV in the same side, the case was defined as "early recurrence" | 1 month | Cervical range of motion | 6 |
| Luryi AL et al. (USA), 2018(a) | Case-control | 1378 | Recurrence was defined as BPPV symptoms with a positive diagnostic maneuver following resolution | Mean 18 months | Head trauma versus idiopathic benign positional vertigo | 9 |
| Luryi AL et al. (USA), 2018(b) | Case-control | 1581 | Recurrence was defined as subjective symptoms following resolution with a diagnostic maneuver again positive for subjective vertigo and objective nystagmus in either ear. | Mean 12 months | Meniere disease | 9 |
| Luryi AL et al. (USA), 2018(c) | Case-control | 1105 | Recurrence of subjective symptoms with a diagnostic maneuver positive for subjective vertigo and objective nystagmus in either ear | Mean 20 months | Age, gender, side, head trauma, diabetes, Meniere disease, and number of treatments | 9 |
| Liu XW and Li (China), 2018 | Cohort | 202 | Recurrence of subjective symptoms with a diagnostic maneuver positive for subjective vertigo and objective nystagmus in either ear | Mean 10 months | Duration of vertigo before treatment, the times of repositioning, sex, age, the incubation period of BPPV, and type of canal | 7 |
| Liu et al (Korea), 2013 | Case-control | 86 | All patients were urged to contact us and arrange an immediate office visit if they had recurrence of positional vertigo | Mean 12 months | Trauma | 6 |
| Lee et al (Korea), 2013 | Case-control | 37 | Recurrence was defined as BPPV that occurred >1 month after a successful reposition maneuver. | Mean 12 months | VEMP test | 6 |
| Korres et al (Greece), 2006 | Cohort | 155 | Follow-up care included communication by phone and, in case of recurrence of symptoms, re-examination and repeat of the repositioning procedures. | Mean 24 months | Sex, etiology (idiopathic/truma, duration of BPPV, Cochleovestibular disease, electronystagmography, canal involvement, improper performance of maneuvers) | 7 |
| Kim et al (Korea), 2017 | Case-control | 198 | Recurrent BPPV was defined as the recurrence of BPPV after at least 1 month of a symptom-free interval following previous successful treatment. | ≥12 months | Age, gender, the involved semicircular canal, and bone mineral density | 8 |
| Author (country), year | Study design | Sample size | Recurrence definition | Follow-up time | Identified risk factors | NOS |
|-----------------------|-------------|-------------|-----------------------|----------------|------------------------|-----|
| Kim et al (Korea), 2009 | Case–control | 779 | Recurrence of BPPV was defined as recurrent symptoms and signs of vertigo with positive results in the Dix–Hallpike test after at least 1 month of symptom-free status. | Mean 23 months | Trauma | 5 |
| Kao et al (China), 2009 | Case–control | 218 | | Mean 3 months | Age | 6 |
| Kansu L (Turkey), 2010 | Cohort | 118 | Information was collected as to whether the patient had experienced episodes of BPPV or had received treatment in another clinic during the intervening time. | Mean 64 months | History of head trauma, sex, Migraine, Meniere's disease, and history of ear operation | 8 |
| Guo et al (China), 2010 | Case–control | 186 | All patients were contacted by telephone whether recurrence of positional vertigo | 24 months | Age | 6 |
| Gordon et al (Israel), 2004 | Case–control | 247 | All patients were urged to contact our clinic and arrange an immediate office visit if they had recurrence of positional vertigo. | Mean 22 months | History of head trauma | 6 |
| Del Rio and Arriaga (USA), 2004 | Cohort | 104 | All of the patients were asked to return if vertigo recurred. | 6-15 months | Ear surgery, labyrinthitis/neuronitis, trauma, multifactor disequilibrium, and endolymphatic hydrops | 8 |
| Chen et al (China), 2015 | Cohort | 300 | Recurrence was defined as subjective symptoms following resolution with a diagnostic maneuver again positive for subjective vertigo in either ear within one year. | 12 months | Age, gender, side, diabetes, hypertension, posterior circulation ischemia, oral intake of calcium tablets, hyperlipidemia, overwork, sleep disorders, long use of computers, and being on business frequently | 6 |
| Chen et al (China), 2019 | Case–control | 42 | BPPV recurred more than 1 month after successful reposition. | Mean 12 months | Vascular evoked myogenic potential (VEMP) | 6 |
| Baas et al (Serbia) 2014 | Cohort | 400 | | 12 months | Sex, age, duration of symptoms, etiologic factors, migraines, osteoporosis, vascular risk factors, endocrine diseases, localization of otoconia, and simultaneous involvement of multiple canals. | 6 |
| Li et al (China), 2019 | Cohort | 424 | Recurrence of positional vertigo or positive Dix–Hallpike test | 6 months | Gender, age, hyperlipidemia, hypertension, diabetes, migraine, osteoporosis | 6 |
| Jing and Li (China), 2019 | Cohort | 569 | Recurrence of positional vertigo | 12 months | Gender, age, hyperlipidemia, hypertension, diabetes, migraine, osteoporosis, trauma, Meniere disease, and otitis media | 6 |
| Chen et al (China), 2018 | Cohort | 175 | Recurrence of positional vertigo lasting less than 3 minute | 12 months | Gender, age, semicircular canal attacked, times of repositioning treatment, hyperlipidemia, diabetes, and migraine | 5 |
| Lv Xiaoyu et al (China), 2016 | Cohort | 1011 | Recurrence of positional vertigo or positive Dix–Hallpike test | Mean 30 months | Gender, age, hyperlipidemia, hypertension, diabetes, and migraine | 7 |
| Han Q (China), 2016 | Cohort | 327 | Recurrence of positional vertigo | 12 months | Gender, age, hyperlipidemia, hypertension, diabetes, migraine, cervical spondylosis, and head injury | 7 |
| Yuan et al (China), 2015 | Cohort | 90 | | 12 months | Gender, age, hyperlipidemia, hypertension, diabetes, and migraine | 5 |
| Jin XH et al (China), 2015 | Cohort | 99 | Recurrence of positional vertigo | 6 months | Hypertension, diabetes, hyperlipidemia, and cervical spondylosis | 5 |
| Zhang et al (China), 2015 | Cohort | 100 | Recurrence of positional vertigo | 12 months | Age, gender, cervical spondylosis, hypertension, hyperlipidemia, and diabetes | 6 |
| Qin and Cai (China), 2018 | Cohort | 100 | Recurrence of positional vertigo | 3 months | Gender, age, hyperlipidemia, diabetes, hypertension, and vomit | 6 |
| Wang JB (China), 2016 | Cohort | 200 | Recurrence of positional vertigo | 3 months | Gender, age, hyperlipidemia, diabetes, hypertension, semicircular canal attacked, times of repositioning treatment, migraine, head injury, history of ear operation, Meniere's disease, and otitis media | 7 |
| Fang and Jiang (China), 2016 | Cohort | 186 | Recurrence of positional vertigo | 3 months | Gender, age, hyperlipidemia, diabetes, hypertension, and otitis media | 6 |
| Zhou et al (China), 2013 | Cohort | 220 | Recurrence of positional vertigo and positive Dix–Hallpike test | Mean 13 months | Gender, age, hyperlipidemia, diabetes, hypertension, semicircular canal attacked, times of repositioning treatment, migraine, head injury, history of ear operation, Meniere disease, and otitis media | 6 |

Abbreviation: BPPV, benign paroxysmal positional vertigo; NOS, Newcastle-Ottawa Scale.

* means undefined.
Included studies were then tested for heterogeneity using the χ² test with significance set at P < .10 and the amount of heterogeneity was quantified by the I² statistic as follows: (1) low 25%, (2) moderate 50%, and (3) high 75%. Where statistical heterogeneity (I²) was >50%, a random effects model was used. Where statistical heterogeneity (I²) was <50%, a fixed-effects model was used. Where meta-analysis was not possible, a narrative summary of study results is provided. Publication bias was visually evaluated using a funnel plot and Harbord test. Meta-analyses were conducted where feasible for each risk factor using Stata SE (version 15.0) software.

Results

Study Selection

According to the search strategy, 4076 records were initially identified, in which 2036 articles were excluded because of duplication and 1736 articles were excluded after screening of abstract. After further evaluation of remaining 99 full-text studies, sixty eligible studies with 36 646 patients were finally included in this meta-analysis.9-12,13,16,18,22-78 A PRISMA flow diagram was presented to describe the detail selection process (Figure 1).

Study Characteristics

Sixty-three studies examined 24 risk factors for recurrence of BPPV, and they included 36 646 participants. Twenty-three were retrospective cohort studies, and 37 were retrospective case–control studies. The number of patients in the included studies ranged from 42 to 21355 (Table 1). Studies were conducted in Israel (4), Korea (11), Japan (4), Germany (1), Egypt (2), India (1), Italy (2), United States (4), Uruguay (1), Croatia (1), Greece (1), Turkey (1), Serbia (1), and China (26; Table 1).
Quality Assessment

All 60 articles were observational studies. Based on the NOS, 50 studies were deemed to have high quality, while 10 studies were judged to be of moderate quality (Table 1). Supplementary Table S1 provides an overview of the results of the risk of bias assessments.

Findings

Thirty risk factors were identified. Thirteen of these were found to be risk factors for recurrence of BPPV: gender, age, hyperlipidemia, diabetes, hypertension, migraine, cervical spondylosis, osteopenia/osteoporosis, trauma, otitis media, ocular vestibular evoked myogenic potential (oVEMP), cervical vestibular evoked myogenic potential (cVEMP), and long use of computers. Side, type of the involved semicircular canals, smoking, alcohol consumption, stroke, ear surgery, duration of vertigo before treatment, the times of repositioning, Meniere disease, sleep disorders, hypercholesterolemia, and 25-hydroxy vitamin D did not correlate with BPPV recurrence (Table 2).

Gender. Forty-three studies provided data on gender, and they included 29 035 patients. Female are more likely to relapse than men (OR = 1.22, 95% CI: 1.155-1.288). We did not find significant heterogeneity among these studies ($I^2 = 1.3\%$, $P = .000$) in a fixed-effects model (Figure 2).

Age. Six studies examined age as a risk factor for recurrence of BPPV, and they included 22 701 participants. Patients older than 65 years are more likely to relapse when compared to patients <65 years (OR: 1.526; 95% CI: 1.432-1.626, $I^2 = 0\%$, $P = .000$; Figure 3).

Hyperlipidemia. A high heterogeneity was detected ($I^2 = 82\%$, $P = .003$) to analyze data from 13 studies and a random effects model was applied. Overall results indicate that patients with hyperlipidemia are twice as likely to have recurrence BPPV when compared with patients without hyperlipidemia (OR 2.347, 95% CI: 1.335-4.126). As the heterogeneity was significant, we tried to seek heterogeneity sources through stratification analysis. The results showed that area and study design were not sources of heterogeneity. Stratified analysis based on follow-up time can significantly reduce heterogeneity (Figure 4).

Diabetes mellitus. Seventeen studies reported diabetes mellitus as a risk factor for recurrent BPPV, and they included 25 562 participants. Patients with diabetes mellitus are more likely to relapse when compared to patients without diabetes mellitus (OR 2.867; 95% CI: 1.831-4.490). The analysis was performed with a random effects model for the evidence of $I^2 = 88.6\%$ and $P = .000$. Similarly, in order to investigate potential sources of heterogeneity, we performed subgroup analysis by

---

**Table 2. Meta-Analysis of the Pooled Risk Factors for Recurrent BPPV.**

| Risk factors | No. of study | No. of participants | $I^2$ (%) | R/F | Q-test, $P$ | OR (95% CI) | MD (95% CI) | $P$ |
|--------------|--------------|---------------------|-----------|-----|------------|-------------|-------------|-----|
| Gender (female vs male) | 43 | 29035 | F 1.3 | .447 | 1.22 (1.155 to 1.288) | .000 |
| Age $\geq$ 65 years vs < 65 years | 6 | 22701 | F 0.0 | .446 | 1.526 (1.432-1.626) | .000 |
| Left side vs right side | 8 | 1080 | F 0.0 | .569 | 1.055 (0.806-1.381) | .696 |
| PSC vs HSCA | 11 | 1594 | F 9.2 | .355 | 1.034 (0.770-1.387) | .862 |
| Hyperlipidemia | 13 | 2481 | R 82 | .000 | 2.347 (1.335-4.126) | .003 |
| Diabetes mellitus | 17 | 25562 | R 88.6 | .000 | 2.867 (1.831-4.490) | .000 |
| Hypertension | 18 | 24437 | R 83.2 | .000 | 2.381 (1.667-3.400) | .000 |
| Migraine | 13 | 24123 | R 71.2 | .000 | 1.664 (1.142-2.424) | .008 |
| Cervical spondylosis | 7 | 1335 | F 10.5 | .348 | 1.368 (1.038-1.803) | .026 |
| Smoking | 2 | 491 | F 36 | .211 | 0.691 (0.404-1.181) | .177 |
| Alcohol consumption | 2 | 490 | F 0 | .388 | 0.852 (0.400-1.815) | .679 |
| Osteopenia/osteoporosis | 6 | 22750 | F 1.6 | .406 | 1.385 (1.287-1.491) | .000 |
| Stroke | 2 | 21464 | R 64.3 | .094 | 1.654 (0.670-4.083) | .275 |
| Head trauma | 27 | 28584 | R 76.6 | .000 | 1.622 (1.138-2.311) | .007 |
| Ear surgery | 3 | 21710 | F 0.0 | .855 | 1.403 (0.887-2.218) | .147 |
| Otitis media | 4 | 970 | F 0.0 | .836 | 2.319 (1.231-4.369) | .009 |
| Duration of vertigo before treatment | 4 | 638 | R 98.1 | .000 | 1.028 (-0.389 to 2.446) | .155 |
| Twice or more repositioning vs once repositioning | 3 | 1320 | R 84.8 | .001 | 2.996 (0.712 to 12.606) | .134 |
| Meniere disease | 6 | 2163 | R 62.8 | .020 | 1.274 (0.633 to 2.566) | .497 |
| oVEMP | 3 | 137 | F 0.0 | .801 | 4.992 (2.015 to 12.368) | .001 |
| cVEMP | 3 | 137 | F 0.0 | .733 | 2.428 (1.037 to 5.493) | .033 |
| Sleep disorders | 6 | 1334 | R 90.2 | .000 | 1.465 (0.567 to 3.783) | .430 |
| 25-hydroxy vitamin d | 3 | 540 | R 61.8 | .073 | 0.029 (-0.364 to 0.306) | .865 |
| Hyper cholesterol | 2 | 198 | F 0.0 | .809 | 2.514 (0.984 to 6.427) | .054 |
| Long use of computers | 2 | 328 | F 0.0 | .443 | 2.848 (1.715 to 4.730) | .000 |

Abbreviations: F, fixed effect model; HSC, horizontal semicircular canal; MD, mean difference; PSC, posterior semicircular canal; R, random effect model; VEMP, vestibular evoked myogenic potential.
Li et al

contrasting the area, study design, and follow-up time of included studies. The results showed neither area nor study design could significantly reduce heterogeneity, except follow-up time (Figure 5).

**Hypertension.** Eighteen studies reported hypertension as a risk factor for recurrent BPPV, and they included 24,437 participants. Patients with hypertension are more likely to relapse when compared to patients without hypertension (OR: 2.381; 95% CI: 1.667-3.400). However, statistically significant heterogeneity was observed among these results ($I^2 = 83.2\%$, $P = .000$), which are shown in Figure 6. Stratified analysis based on follow-up time can significantly reduce heterogeneity (Figure 7).

**Migraine.** Thirteen studies reported migraine as a risk factor for recurrent BPPV, and they included 24,123 participants. Patients with migraine are more likely to relapse when compared to patients without migraine (OR: 1.664; 95% CI: 1.142-2.424). The analysis was performed with a random effects model for the evidence of $I^2 = 71.2\%$ and $P = .008$. Stratified analysis based on follow-up time can significantly reduce heterogeneity (Figure 7).

**Cervical spondylosis.** Seven studies reported cervical spondylosis as a risk factor for recurrent BPPV, including 1335 participants, and a fixed effects model was applied ($I^2 = 10.5\%$, $P = .026$). Patients with cervical spondylosis are more likely to relapse when compared to patients without cervical spondylosis (OR: 1.37; 95% CI: 1.038-1.803; Figure 8).

**Osteopenia/osteoporosis.** Six studies provided data on osteoporosis, and they included 22,750 patients. Patients with osteoporosis are more likely to relapse when compared to patients without osteoporosis (OR: 1.385; 95% CI 1.287-1.491). No significant heterogeneity was found across the results ($I^2 = 1.6\%$, $P = .000$), which are shown in Figure 8.

**Figure 2.** Forest plot of association between gender and recurrent BPPV. BPPV indicates benign paroxysmal positional vertigo.
Figure 3. Forest plot of association between age (≥65 years or <65 years) and recurrent BPPV. BPPV indicates benign paroxysmal positional vertigo.

Figure 4. Forest plot of association between hyperlipidemia and recurrent BPPV. BPPV indicates benign paroxysmal positional vertigo.
Head trauma. Twenty-seven studies reported head trauma as a risk factor for recurrent BPPV, and they included 28,584 participants. Patients with head trauma are more likely to relapse when compared to patients without head trauma (OR: 1.622; 95% CI: 1.138-2.311, I² = 76.6%, P = .007, random effect model). Stratified analysis based on area can significantly reduce heterogeneity (Figure 9).

Otitis media. Four studies reported otitis media as a risk factor for recurrent BPPV, and they included 970 participants. Patients with otitis media are more likely to relapse when compared to patients without otitis media (OR: 2.319; 95% CI: 1.231-4.369) with no evidence of heterogeneity in fixed effect model (Figure 8).

Vestibular evoked myogenic potential. Three studies reported abnormal VEMP as a risk factor for recurrent BPPV, and they included 137 participants. Patients with abnormal VEMP are more likely to relapse when compared to patients with normal VEMP (oVEMP: OR = 4.992; 95% CI: 2.015-12.368, I² = 0.0%, P = .801; cVEMP: OR = 2.428; 95% CI: 1.073-5.493, I² = 0.0%, P = .733), with no evidence of heterogeneity in fixed effect model (Figure 10).

Long use of computers. Two studies reported long use of computers as a risk factor for recurrent BPPV, and they included 328 participants. Patients who use computers for a long time are more likely to relapse when compared to patients who don’t (OR = 2.848; 95% CI: 1.715-4.730) with no evidence of heterogeneity in fixed effect model (I² = 0.0%, P = .443; Figure 10).

Meniere disease. Six studies reported Meniere’s disease as a risk factor for recurrent BPPV, and they included 2163 participants. There aren’t association between Meniere’s disease and recurrence of BPPV (OR = 1.274; 95% CI: 0.633-2.566). Moderate heterogeneity was found in a random effects model (I² = 62.8% and P = .020; Figure 11).

Risk factors not associated with recurrent BPPV. The meta-analysis of side, type of the involved semicircular canals, smoking, alcohol consumption, stroke, ear surgery, duration of vertigo before treatment, the times of repositioning, hypercholesterolemia, sleep disorders, and 25-hydroxy vitamin D which did not correlate with recurrent BPPV were presented in supplement materials.
follow-up time > 6 month
Liu et al. (2008) 0.42 (0.11, 1.64) 3.72
Su-Jin Han CYK et al. (2019) 1.26 (1.18, 1.34) 8.21
Wang Yun et al. (2018) 1.62 (0.58, 4.47) 4.93
Tian Yongsheng et al. (2018) 0.88 (0.28, 2.77) 4.46
Sreensivas et al. (2019) 3.23 (1.01, 10.31) 4.39
Rhim Gil et al. (2019) 1.24 (0.65, 2.37) 6.48
So Young Kim et al. (2017) 17.01 (6.14, 47.10) 9.92
Cheng QingGuo et al. (2015) 1.22 (0.61, 2.44) 6.29
Jing XiaoZhong et al. (2018) 2.17 (1.22, 3.84) 6.80
Chen Xiao Xu et al. (2018) 1.97 (1.04, 3.75) 6.49
Chen Xiao Xu (a)et al. (2018) 1.54 (0.39, 6.10) 3.70
Han Qian et al. (2016) 1.90 (1.08, 3.33) 6.93
Yuan YuMei et al. (2015) 1.71 (0.51, 5.67) 4.25
Subtotal (I-squared = 68.2%, p = 0.000) 1.74 (1.25, 2.42) 71.49
follow-up times ≤ 6 month
Li Yu Juan et al. (2019) 1.78 (1.17, 2.72) 7.38
Jin Xue Hong et al. (2015) 3.07 (1.08, 8.75) 4.81
Qin Hai Yan et al. (2018) 22.39 (7.19, 69.70) 4.48
Wang Ji Bao et al. (2016) 6.90 (3.22, 14.81) 5.97
Fang Fang et al. (2015) 7.00 (3.18, 15.42) 5.06
Subtotal (I-squared = 84.7%, p = 0.000) 5.35 (2.22, 12.92) 28.51
Overall (I-squared = 83.2%, p = 0.000) 2.36 (1.67, 3.40) 100.00
NOTE: Weights are from random effects analysis

Figure 6. Forest plot of association between hypertension and recurrent BPPV. BPPV indicates benign paroxysmal positional vertigo.

Sensitivity Analyses
Because of the heterogeneity between some studies, the results of meta-analysis may have changed significantly. We used sensitivity analysis to verify the reliability of the meta-analysis finding in this study. Statistical analysis of studies on hyperlipidemia, diabetes, hypertension, migraine, Meniere’s disease, and head trauma showed that the results of the meta-analysis did not change after each study was excluded. This indicated that the meta-analysis had good stability, and the results of the meta-analysis were reliable (Figure 12–16).

Subgroup Analyses
Studies on hyperlipidemia, diabetes, hypertension, migraine, and head trauma showed high heterogeneity. We searched for the source of heterogeneity of these studies through subgroup analysis and meta-regression. The included studies were divided into 2 groups according to the region, follow-up period (≤6 months or >6 months), and study design. We also analyzed the findings of this study by performing meta-regression. Follow-up time has a statistically significant contribution to the heterogeneity in the analysis of hyperlipidemia, diabetes, hypertension, migraine (P < .05), area, and heterogeneity in the analysis of head trauma (P < .05), indicating that follow-up time and area may be the source of heterogeneity in the study, but it cannot explain total heterogeneity.

Assessment of Publication Bias
To determine the potential publication bias of the literature, we performed Harbord test. The publication bias was significant for hypertension, head trauma, diabetes (P = .009, P = .015, P = .002). We did not find any existence of publication bias in the results of hyperlipidemia, migraine, and Meniere’s disease (P = .724, P = .114, P = .290; Figure 11).

Discussion
This systematic review and meta-analysis provide comprehensive data on the risk factors contributing to recurrent BPPV. We find female gender, age (≥65 years), hyperlipidemia, diabetes, hypertension, migraine, cervical spondylosis, osteopenia/osteoporosis, trauma, otitis media, abnormal VEMP, and long use of computers are risk factors for recurrence of BPPV, and there is no association between side, type of the involved semicircular canals, smoking, alcohol consumption, stroke, ear surgery, duration of vertigo before treatment, the times of repositioning, Meniere’s disease, sleep disorders, 25-hydroxy vitamin D, and the recurrence of BPPV.
Although paroxysmal positional vertigo is the most frequently observed pathology in otoneurological clinical practice, a definitive causative factor has not been identified yet. There are 2 main hypotheses to explain the development of BPPV. Schuknecht proposed the cupulolithiasis theory, which is based on the attachment of otolithic debris to the cupula in the crista ampullaris. Hall et al proposed the theory of canalithiasis, which is based on the presence of free-floating debris in the canal. Both these theories indicate that the presence of foreign particles in the semicircular canal may be the cause of vertigo. How these particles detach from utricle is still unclear. When position changes, particles move in the endolymph with the help of gravity and thus cause abnormal displacement of the cupula and aberrant neural stimulation, producing vertigo.

Some studies showed no correlation between gender, age, and recurrent BPPV. However, Chau et al and von Brevern M et al reported that age and gender were related to recurrent BPPV. Our study showed that female and older patients (>65 years) have a higher level of relapses of BPPV (OR = 1.22, P = .000; OR = 1.526, P = .000). A menopause-related reduction in the secretion of female hormones may be involved in this phenomenon. A decrease in estrogen secretion may affect calcium/bone metabolism. Calcium metabolism also plays a chief role in the synthesis/absorption of otoconia made of calcium carbonate and so might be an etiological factor in the onset and recurrence of BPPV. Additionally, it is believed that during lifetime the number and volume of ooliths are progressively reduced and the interconnecting fibers between the ooliths may weaken from age-related reduction of calcium carbonate crystals in the process of demineralization. It was also supposed that age-related altered endolymphatic pH and calcium concentration may contribute to the pathogenesis of BPPV and worsen the symptoms.

The posterior SCC is the more frequently involved SCC in the pathogenesis of BPPV. The explanation for this is the anatomical location of the SCC at the most dependent position in the vestibular apparatus in a standing person. Von Brevern et al found BPPV predominantly affects the right labyrinth, and the probably reason is the habit—of most patients—of sleeping on the right side. Recent studies showed that side and semicircular canal attacked were not associated with recurrent BPPV. Our meta-analysis results also showed that the recurrence of BPPV wasn’t related to side and semicircular canal attacked (P > .05).

Increasing studies have proposed that systemic disease, including hyperlipidemia, hypertension, diabetes, cervical spondylosis, and stroke, could also increase the recurrence of BPPV. We conducted a meta-analysis of these indicators, and hyperlipidemia, hypertension, diabetes, and cervical spondylosis showed statistical significance (P < .05). This
may be related to the known effect of hypertension and vascular disease on the inner ear, causing reduced blood flow to the labyrinth and contributing to dislodgement of otoliths and manifestation of BPPV. In addition to vascular damage, diabetes generates a balance disorder mediated by variations of blood glucose and plasma insulin levels with subsequent cupular deposits and free-floating debris in the semicircular canals. In a case–control histopathologic study of temporal bones in humans, the authors compared the prevalence of cupular and free-floating otoconia in the SCCs between the temporal bones of patients with type 1 diabetes and normal controls. They found that the presence of otoconia in the horizontal and
posterior SCC was significantly higher in the patient group than in the control group. It has been reported that the occurrence of BPPV was higher in people with type 2 diabetes (46%) compared to those without the metabolic disease (37%). In a recent report, Jáuregui-Renaud et al. studied the function of horizontal SCCs and utricle in patients with type 2 diabetes, who did not have any history of dizziness or other vestibular symptoms. The authors found that the patients had downsized
Figure 13. The funnel plots, Harbord test, sensitivity analysis of hyperlipidemia.

Figure 14. The funnel plots, Harbord test, sensitivity analysis of migraine.

Figure 15. The funnel plots, Harbord test, sensitivity analysis of diabetes.

Figure 16. The funnel plots, Harbord test, sensitivity analysis of head trauma.
responses to unilateral centrifugation compared to healthy volunteers, but their responses to horizontal SCC stimulation were similar and they had also a larger sway area and a longer sway path in the test of posturography. They assumed that utricular function may be defective even in the absence of horizontal SCC involvement or a history of falls. Similarly, in a postmortem study of temporal bones, containing 1031 semicircular canals, basophilic deposits (supposedly degenerated otoconia) were observed in 22% of the semicircular canal cupulae. Interestingly, none of those cases had a history of BPPV. It has been suggested that the size of the debris within the semicircular canal needs to reach a critical level before aberrant neural stimulation and BPPV symptoms develop.\(^{81,96}\) Circulation to the inner ear is from the vertebrobasilar system, primarily the anterior inferior cerebellar artery, which branches into the anterior vestibular artery. Its anatomical location within the inner ear causes the labyrinth particularly vulnerable to ischemia. The association between recurrent and stroke has been proposed by Su-Jin Han et al.\(^{77}\) Wada et al\(^{97}\) used carotid ultrasonography to evaluate the intima–media thickness of the common carotid artery in patients with BPPV and vestibular hypofunction. The study found that the percentage of abnormal intima–media thickness of common carotid arteries was significantly higher in patients with BPPV than those with other vestibular disorders. A study by Zhang et al\(^{98}\) also admitted increased abnormalities in the vertebrobasilar arteries of BPPV patients. The severity of vertigo was correlated with vertebral artery stenosis, occlusion, or tortuosity.\(^{98}\) These reports demonstrated that patients with BPPV had a higher prevalence of arteries injury. It is believed that BPPV can be a sequela to labyrinthine ischemia that probably facilitates detachment of otoconia from the otolith membrane.\(^{99}\) Additionally, diabetes mellitus or hyperuricemia can sometimes lead to metabolic acidosis in the blood and result in low pH in the endolymphatic fluids, which will facilitate the breakdown of calcium carbonate otooliths.\(^{100,101}\) Theoretically, age, hyperlipidemia, hypertension, diabetes, and stroke all serve as vascular risk factors and one could wonder that the common predisposing factor of BPPV might be ischemia. Yet we did not find an association between BPPV and other well established vascular risk factors such as stroke, smoking, and alcohol consumption \((P > .05).\)

Back in 2003, Vibert et al proposed a connection between BPPV, osteoporosis, and osteopenia.\(^{84}\) Since then another independent group also noted that bone metabolism has a connection to BPPV.\(^{102}\) Moreover, there was a study demonstrating that the treatment of osteoporosis may have a protective effect against BPPV.\(^{103}\) Recent research brought to light the impact of the vitamin D levels on the BPPV with decreased levels being associated with its occurrence and more frequent recurrence.\(^{18,104,105}\) Recent studies demonstrated a possible seasonality to BPPV, with fewer cases occurring during the summer months.\(^{106,107}\) Theories behind this trend propose calcium homeostasis to play a key role as serum Vitamin D levels surge with increasing daylight. However, Korpon et al suggests that the variable with the single strongest correlation between BPPV and seasonal variations is not sunlight or UV index, but rather barometric pressure.\(^{108}\) Yet, the correlative evidence may be weak because recent evidence suggests such associations to be purely coincidental.\(^{109}\) Yang et al\(^{110}\) evaluated the relationship between BMD and Vitamin D with the presence and recurrence of BPPV. The authors found that low BMD in women and low serum Vitamin D levels in men were significantly associated with the recurrence of BPPV, whereas age was an independent predictor of recurrence. In a rat model with impaired calcium turnover, due to the bilateral ovariectomy, the density of otoconia was decreased and their size was increased compared to the normal group.\(^{111}\) Our results indicate that osteoporosis/osteopenia was contributors to the recurrence of BPPV, while vitamin D was not.

Our analysis found that migraine is a risk factor for BPPV recurrence. Migraine and BPPV are among the most frequently encountered diseases in otoneurologic clinics. The pathophysiologic mechanisms of migraine is still not clear, several studies have hypothesized that genetic and vascular factors and cortical spreading depression may be the underlying mechanism.\(^{112-114}\) The mechanism for the vestibular symptoms and signs associated with migraine is poorly understood.\(^{115}\) Vasospasm of the labyrinthine arteries is a possible mechanism because vasospasm is a well-documented phenomenon with migraine.\(^{115}\) Repeated vasospasm may stress and injury the vestibular cells, inducing the dropping of otoconia from the macula. In addition, elimination of the inner-ear microvasculature as a result of vasospasm may generate cochlear symptoms, such as hearing disturbance and vestibular symptoms.\(^{116}\) Additionally, recurrent vasospasm is associated with the oxidative stress of endothelial cells, which is a possible pathogenic mechanism common to both migraine and BPPV.\(^{117,118}\) The specific pathway for oxidative stress in migraine has not yet been acknowledged, but several studies have announced a reduction in superoxide dismutase activity in patients with migraine.\(^{119-121}\) In a study of oxidative stress associated with BPPV, levels of pro-inflammatory mediators, such as interleukin 1\(\beta\) (IL-1\(\beta\)), IL-6, and tumor necrosis factor, were raised in the serum of patients experiencing a BPPV attack and declined after repositioning maneuvers such as the Epley maneuver.\(^{118}\) In addition, total antioxidant capacity and paraoxonase levels, which are antioxidant parameters, were decreased during a BPPV attack.\(^{118}\) Therefore, oxidative stress and inflammatory processes in the inner ear may be connected with the formation and migration of the otolith. Probably, patients with migraine have recurrent damage to the inner ear (due to vasospasm or some other mechanism) that predisposes them to recurrent bouts of BPPV.\(^{122}\)

The relationship between Meniere’s disease and BPPV is complex. The incidence of coexistence of BPPV and Meniere’s disease ranges from 0.5% to 44%.\(^{123,124}\) Predominance of ipsilateral existence of BPPV and Meniere’s disease have been reported in the majority of studies, which indicates a probably causal relationship between these 2 disorders.\(^{125}\) There is radiological evidence that detached saccular otoconia may cause obstruction of the reuniting duct and result in endolymphatic hydrops.\(^{126}\) The association between BPPV and Meniere’s
disease has been confirmed by histopathologic temporal bone studies reporting significantly higher incidence of cupulor free-floating deposits in SCCs in patients with Meniere’s disease than in controls. Additionally, repeated episodes of hydrops may eventually generate sacculotricular degeneration and detachment of the otoconia. Patients with unilateral hearing loss generally would like to sleep lying on the ear with hearing loss to keep the better hearing ear in the open environment. Shim et al. have announced that sleeping habit is closely related with the affected side in BPPV. Otoconial debris dislodged from the utricle may fall into the lateral or PSCs of the undermost ear during sleep. This may account for more the common lateral canal involvement and ipsilateral occurrence of Meniere’s disease and BPPV. Dornhoff and Colvin suggested that Meniere’s disease was associated with recurrent BPPV. Tanimoto et al reviewed risk factors in recurrent BPPV. They found that 75% of them have endolymphatic hydrops and all were in the same ear with BPPV. However, in a larger series, Luryi et al. reported that there was no association between Meniere’s disease and recurrence of BPPV, which was keeping in line with our analysis result \( (P > .05). \) Gross et al. noted that BPPV in Meniere’s disease was poorly response to repositioning maneuvers. This phenomenon could be explained by several potential mechanisms. Anatomical changes of labyrinth due to hydrops probably are a main reason for intractability of BPPV in Meniere’s disease. Partial obstruction of the posterior SCC by a dilated saccule could also result in adherence of otooliths to the membranous labyrinth. Partial obstruction allows otooliths to move within canals and keeps them from returning to vestibules. Stricture of the membranous labyrinth resulting from loss of its resilience after repeated distension due to endolymphatic hydrops may be another cause because the membrane may collapse inward and lead to severe narrowing of the SCC.131

Approximately 13% of patients with traumatic brain injury report positional vertigo, and half of these patients have BPPV. When canalolithiasis occurs briefly after an impulsive head trauma (rapid head deceleration), a causative relationship may be suggested.134 When compared with idiopathic BPPV (i-BPPV), traumatic BPPV (t-BPPV) was associated with several poor prognostic features, including a higher rate of bilateral disease and a higher rate of recurrence. A subsequent whiplash injury might be responsible of the otoconial detachment, and microscopic hemorrhages, or “tissue shearing,” results in biochemical changes that boost the formation of otoconial clots. Following a successful maneuver, these microscopic changes may reactivate the production of new clots, explaining the recurrence of BPPV. While, in a large series, there was no important differences in outcomes were revealed, with the t-BPPV group having rates of resolution and recurrence similar to those in the i-BPPV group and requiring a similar number of treatment visits.61 Our result find that head trauma is a risk factor for recurrent BPPV and there is a high heterogeneity. This may be the result of lacking definite criteria for traumatic BPPV. According to Riga et al, for a causative association to be valid, BPPV should occur on the same side as the causative disease and the clinical symptoms should appear either concurrently or soon after the manifestation of the primary disease.136 Studies that specifically mention BPPV as one of the possible causes of posttraumatic dizziness or vertigo are lacking diagnostic clarity.

Dysfunction of the otoconials has been a suspected pathogenesis of BPPV. There have been some reports of VEMP abnormalities in patients with BPPV. In explaining the pathophysiology of BPPV, the concept of a degenerative process that affects the macula of the utricle causing detachment of otooliths has gained popular support.132 Nonetheless, there were only a few reports of association between recurrence of BPPV and VEMP test. In our analysis, there was only 3 paper providing these data, and we find abnormal VEMP is a risk factor for the recurrence of BPPV, which is in accord with the findings by Lee et al. In BPPV, the degenerative process that affects the macula of the utricle and causes detachment of the otooliths might also affect the macula of the saccule.

Studies have found that otooliths can easily fall off the otoconial membrane and cause BPPV when exposed to inflammation, infection, or low pH. Ca\(^{2+}\) concentration in the endolymph may be increased due to recurrent inflammation, which will destroying the normal equilibrium between otolith formation and dissolution, and thus the likelihood of BPPV increases significantly.100 Otitis media and long use of computers are also risk factors for relapse in our analysis, but only 4 and 2 studies were included, and the quality of the studies was not high. Therefore, the results should be interpreted with caution. More high-quality studies are needed in the future to confirm these findings.

**Strengths and Limitations**

Our systematic review has several strengths. This is the first systematic review to comprehensively investigate the risk factors for recurrent BPPV. We used a strict search strategy to screen 6 databases with no language restrictions, including PubMed, Embase, Web of Science, Cochrane Library, CNKI, and Sino Med. Based on the NOS, 51 of 63 included studies scored \( \geq 6 \) stars, which suggested high-quality studies. We included a range of publications involving different ethnic populations from across the world to ensure the applicability of our findings and to investigate a wide range of risk factors for recurrent BPPV. Furthermore, we also determined the heterogeneity between the studies included in subgroup analysis and found that most factors showed low levels of heterogeneity. Our sensitivity analysis showed that the sequential omission of a single study did not significantly influence the observed results and the magnitude of effects.

There are some important limitations to this systematic review that need to be considered. First, some risk factors (hyperlipidemia, diabetes, hypertension, migraine, head trauma, MD) have high degree of heterogeneity between the studies. These may be explained by differences in the criteria used to define recurrence, head trauma, and follow-up time. For
example, the studies that specifically mention BPPV as one of the possible causes of posttraumatic dizziness or vertigo are lacking diagnostic clarity. Therefore, we should treat these results with some caution. Second, according to the figures (Figures 2 and 3), a paper was weighted (%) very highly and thus might have caused a bias. So we reanalyze the results after excluding this article. The results of reanalysis revealed that gender remains a risk factor for recurrent BPPV, while age is not. It implied that the biased weights of this paper might distort the results. Third, some publications involved in our meta-analysis were of low quality. Considering the limited number of studies for some factors (for example stroke), the accuracy and validity of the relationship between these factors and recurrent BPPV may also be questionable. Besides, because of the intrinsic differences in the design of included studies, such as study design, duration of follow-up, and so on, potential bias could not be completely ruled out. Therefore, the results should be interpreted carefully. Last but not least, some studies had fewer cases, and the negative results may not have been published. In terms of the assessment of publication bias, there were apparent publication bias with respect to hypertension, head trauma, and diabetes when using the Harbord test. All of these factors may have led to bias. Although our study had good stability, it cannot be entirely excluded potential bias. More high-quality studies are needed in the future to confirm some of these findings.

Conclusions
This systematic review and meta-analysis evaluated the risk factors for recurrent BPPV. Female, age, migraine, head trauma, otitis media, abnormal VEMP, long use of computers, hyperlipidemia, diabetes, hypertension, osteopenia/osteoporosis, and cervical spondylosis were associated with recurrent BPPV. Identification of these risk factors provides some insight into the falls risk evaluation and contributes to help clinicians counsel patients regarding the importance of follow-up after diagnosis of BPPV. Because of the limited quality and quantity of the included studies, rigorous studies with adequate sample sizes are needed to verify the conclusion.

Authors’ Note
Li, Wang, and Cao designed the study, reviewed the literature, conducted the statistical analysis, drafted the manuscript, and discussed the manuscript. Li, Liu, Zheng, Han, and Jing generated summary tables and edited pictures. Li, Ma, and Xia significantly contributed to the study design. Li, Yu contributed to the embellishment of language and revision of the manuscript.

Acknowledgments
The authors thank all the people for their work in the literature collecting, manuscript compiling, and their help with this work. The authors would like to express our gratitude to the reviewers and editors.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Shichang Li https://orcid.org/0000-0003-1084-1252
Lisheng Yu https://orcid.org/0000-0002-5482-6954

Supplemental Material
Supplemental material for this article is available online.

References
1. Bárány E. Diagnose yon krankheitserscheinungen im bereiche des otolithenapparat. Acta Oto-Laryngologica. 1920;2(3):434-437. doi:10.3109/00016482009123103
2. Lemajic-Komazec S, Komazec Z. Initial evaluation of vertigo. Medicinski pregled. 2006;59(11-12):585-590. doi:10.2298/ mpns0612585 l
3. Steenerson RL, Cronin GW, Marbach PM. Effectiveness of treatment techniques in 923 cases of benign paroxysmal positional vertigo. Laryngoscope. 2005;115(2):226-231. doi:10.1097/01. mlg.0000154723.55044.b5
4. Kim JS, Zee DS. Clinical practice. Benign paroxysmal positional vertigo. N Engl J Med. 2014;370(12):1138-1147. doi:10.1056/ NEJMcp1309481
5. Honrubia V, Baloh RW, Harris MR, Jacobson KM. Paroxysmal positional vertigo syndrome. Am J Otol. 1999;20(4):465-470.
6. Riggio F, Dispenza F, Gallina S, Kulamarva G, Gargano R, Speciale R. Management of benign paroxysmal positional vertigo of lateral semicircular canal by Gufoni’s manoeuvre. Am J Otolaryngol. 2009;30(2):106-111. doi:10.1016/j.amjoto.2008.03.001
7. Dorigueto RS, Mazzetti KR, Gabilan YPL, Ganaça FF. Benign paroxysmal positional vertigo recurrence and persistence. Brazil J Otorhinol. 2009;75(4):565-572. doi:10.1016/S1808-8694(15)30497-3
8. Casani AP, Cerchiai N, Navari E. Paroxysmal positional vertigo despite complete vestibular impairment: the role of instrumental assessment. Acta Otorhinolaryngol Ital. 2018;38(6):563-568. doi:10.14639/0392-100x-1549
9. Sakaida M, Takeuchi K, Ishinaga H, Adachi M, Majima Y. Long-term outcome of benign paroxysmal positional vertigo. Neurology. 2003;60(9):1532-1534. doi:10.1212/01.wnl.0000061477. 03862.4d
10. Brandl T, Huppert D, Hecht J, Karch C, Strupp M. Benign paroxysmal positioning vertigo: a long-term follow-up (6-17 years) of 125 patients. Acta Oto-Laryngologica. 2006;126(2):160-163. doi:10.1080/00016480500280140
11. Do YK, Kim J, Park CY, Chung MH, Moon IS, Yang HS. The effect of early canalith repositioning on benign paroxysmal
26. Sunami K, Tochino R, Tokuhara Y, et al. Factors associated with recurrence of BPPV. *Equilibrium Res.* 2005;64(2):64-70. doi:10.3757/jser.64.64

25. Pollak L, Stryjer R, Kushner M, Flechter S. Approach to bilateral benign paroxysmal positioning vertigo. *Ame J Otolaryngol Head Neck Med Surg.* 2006;27(2):91-95. doi:10.1016/j.amjoto.2005.07.012

24. Gordon CR, Levite R, Joffe V, Gadoth N. Is posttraumatic benign positional vertigo different from the idiopathic form? *Arch Neurol.* 2004;61(10):1590-1593. doi:10.1001/archneur.61.10.1590

23. Del Rio M, Arriaga MA. Benign positional vertigo: prognostic factors. *Otalaryngol Head Neck Surg.* 2004;130(4):426-429. doi:10.1016/j.otohns.2003.12.015

22. Kansu L, Avci S, Yilmaz I, Ozluoglu LN. Long-term follow-up of patients with posterior canal benign paroxysmal positional vertigo. *Acta Otolaryngol.* 2011;131(4):377-381. doi:10.3109/000164810.2011.534113

21. Ahn SK, Jeon SY, Kim JP, et al. Clinical characteristics and treatment of benign paroxysmal positional vertigo after traumatic brain injury. *J Trauma.* 2011;70(2):442-446. doi:10.1097/TA.0b013181d0c3d9

20. Lee JD, Park MK, Lee BD, Lee TK, Sung KB, Park JY. Abnormality of cervical vestibular-evoked myogenic potentials and ocular vestibular-evoked myogenic potentials in patients with recurrent benign paroxysmal positional vertigo. *Acta Otolaryngol.* 2013;133(2):150-153. doi:10.3109/00016489.2012.723823

19. Korres S, Balatsouras DG, Ferekidis E. Prognosis of patients with benign paroxysmal positional vertigo treated with repositioning manoeuvres. *J Laryngol Otol.* 2006;120(7):528-533. doi:10.1017/s0022215106000958

18. Liu X, Li G. Clinical study of benign paroxysmal positional vertigo in old age. *Arch Neurol.* 2003;60(4):426-429. doi:10.1001/archneur.60.12.653759

17. Zhang Z, Zhang R. Clinical study of benign paroxysmal positional vertigo of posterior semicircular canal. *Res Vestib Sci.* 2011;10(2):63-67.

16. Liu H. Presentation and outcome of post-traumatic benign paroxysmal positional vertigo. *Acta Oto-Laryngologica.* 2012;132(8):803-806. doi:10.3109/00016489.2012.657359

15. Li et al. Clinical features of recurrent benign paroxysmal positional vertigo treated with repositioning manoeuvres. *J Laryngol Otol.* 2006;120(7):528-533. doi:10.1017/s0022215106000958

14. De Stefano A, Dispensa F, Suarez H, et al. A multicenter observational study on the role of comorbidity factors in the recurrent episodes of benign paroxysmal positional vertigo. *Auris Nasus Larynx.* 2014;41(1):31-36. doi:10.1016/j.anl.2013.07.007

13. Perez P, Franco V, Cuesta P, Aldama P, Alvarez MJ, Mendez JC. Recurrence of benign paroxysmal positional vertigo. *Otol Neurotol.* 2012;33(3):437-443. doi:10.1097/MAO.0b013e3182487778

12. Tanimoto H, Doi K, Nishikawa T, Nibu Kl. Risk factors for recurrence of benign paroxysmal positional vertigo. *J Otalaryngol Head Neck Surg.* 2008;37(6):832-835. doi:10.2310/7070.2008.0A0188

11. Yamanaka T, Shirota S, Sawai Y, Murai T, Fujita N, Hosoi H. Osteoporosis as a risk factor for the recurrence of benign paroxysmal positional vertigo. *Laryngoscope.* 2013;123(11):2813-2816. doi:10.1002/lary.24099

10. Talaat HS, Abuhadied G, Talaat AS, Abdelaal MSS. Low bone mineral density and vitamin D deficiency in patients with benign positional paroxysmal vertigo. *Ear Arch Otorhinolaryngol.* 2015;272(9):2249-2253. doi:10.1007/s00415-014-5175-3

9. Bhattacharyya N, Baugh RF, Orvidas L, et al. Clinical practice guideline: benign paroxysmal positional vertigo. *Otalaryngol Head Neck Surg.* 2008;139(5 Suppl 4-S):S47-S81. doi:10.1016/j.otohns.2008.08.022

8. Higgs JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ (Clin Res ed).* 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557

7. Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomised intervention studies. *Health Technol Assess (Winchester, England).* 2003;7(27):iii-x, 1-173. doi:10.3310/hta7270

6. Gordon CR, Levite R, Joffe V, Gadoth N. Is posttraumatic benign paroxysmal positional vertigo different from the idiopathic form? *Arch Neurol.* 2004;61(10):1590-1593. doi:10.1001/archneur.61.10.1590

5. Del Rio M, Arriaga MA. Benign positional vertigo: prognostic factors. *Otalaryngol Head Neck Surg.* 2004;130(4):426-429. doi:10.1016/j.otohns.2003.12.015

4. Pollak L, Kushnir M, Shpirer Y, Zomer Y, Flechter S. Approach to benign paroxysmal positional vertigo in old age. *Israel Med Assoc J.* 2005;7(7):447-450.

3. Korres S, Balatsouras DG, Ferekidis E. Prognosis of patients with benign paroxysmal positional vertigo treated with repositioning maneouvres. *J Laryngol Otol.* 2006;120(7):528-533. doi:10.1017/s0022215106000958

2. Liu X, Li G. Clinical study of benign paroxysmal positional vertigo in old age. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 2009;23(7):304-306.

1. Liu SY, Han SH, Kim YH, Park MH. Clinical features of recurrence and osteoporotic changes in benign paroxysmal positional vertigo. *Auris Nasus Larynx.* 2017;44(2):156-161. doi:10.1016/j.anl.2016.06.006

0. Gordon CR, Levite R, Joffe V, Gadoth N. Is posttraumatic benign paroxysmal positional vertigo different from the idiopathic form? *Arch Neurol.* 2004;61(10):1590-1593. doi:10.1001/archneur.61.10.1590
41. Zhou Yong GX, Li S, Xiang Yang Z. Analysis of recurrence of benign paroxysmal positional vertigo and its influencing factors. *J Pract Med*. 2013;29(15):2509-2511.

42. Babac S, Djeric D, Petrovic-Lazic M, Arsovic N, Mikic A. Why do treatment failure and recurrences of benign paroxysmal positional vertigo occur? *Otol Neurotol*. 2014;35(6):1105-1110. doi: 10.1097/mao.0000000000000417

43. Chen Q, Wang X, Mao Z, Zheng Y, Liu J, Peng L. Causes of the recurrence of benign, paroxysmal positional vertigo. *Chine J Phys Med Rehab*. 2015;37(9):683-685.

44. Fang Fang DX, Jiang H. Analysis of risk factors for recurrence of benign paroxysmal positional vertigo by manual reduction. *Clin Med China*. 2015;31(3):211-214.

45. Talaat HS, Abuhadied G, Talaat AS, Abdelaal MS. Low bone mineral density and vitamin D deficiency in patients with benign positional paroxysmal vertigo. *Eur Arch Otorhinolaryngol*. 2015;272(9):2249-2253. doi:10.1007/s00405-014-3175-3

46. Wang Chunyan XF, Wang Y, Wang N, et al. Analysis of factors affecting the recurrence of benign paroxysmal positional vertigo in elderly patients. *Chine J Ger*. 2015;34(7):796-799.

47. Xuehong J. Influencing factors of recurrence of benign paroxysmal positional vertigo. *Pract J Card Cereb Pneum Vasc Dis*. 2015;(9):68-70.

48. Yuan Yumei HR, Jiao Y. Analysis of related factors of benign paroxysmal positional vertigo recurrence. *Chine J Prac Ner Dis*. 2015;(7):97-98.

49. Zhou X, Yu Y, Wu Z, Liu X, Chen X. [The roles of otolith organs in the recurrence primary benign paroxysmal positional vertigo]. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi*. 2015;29(18):1641-1644.

50. Ji-biao W. Analysis of Influencing factors on recurrence of benign paroxysmal positional vertigo after repositioning maneuver. *Neural Injury Function Recon*. 2016;11(2):141-144. doi:10.16780/j.cnki.sjssqncj.2016.02.015

51. Ly Xiaoyu JY, Zhao X. Clinical characteristics and outcome of benign paroxysmal positional vertigo. *Chinese J Stroke*. 2016;11(12):1023-1029. doi:10.3969/j.issn.1673-5765.2016.12.006

52. Picciotti PM, Lucidi D, De Corso E, Meucci D, Sergi B, Paludetti G. Comorbidities and recurrence of benign paroxysmal positional vertigo: personal experience. *Int J Audiol*. 2016;55(5):279-284. doi:10.3109/14992027.2016.1143981

53. Qian H. Clinical Features and Recurrent Risk Factors Analysis of Benign paroxysmal Positional Vertigo. Hebei Medical University; 2016.

54. Rhim GL. Long-term outcomes of canalith repositioning for benign paroxysmal positional vertigo: Kaplan-Meier estimate. *Res Vestib Sci*. 2016;15(1):17-21.

55. Su P, Liu YC, Lin HC. Risk factors for the recurrence of post-semicircular canal benign paroxysmal positional vertigo after canalith repositioning. *J Neurol*. 2016;263(1):45-51. doi:10.1007/s00415-015-7931-0

56. Talaat HS, Kabel AM, Khaliel LH, Abuhadied G, El-Naga HA, Talaat AS. Reduction of recurrence rate of benign paroxysmal positional vertigo by treatment of severe vitamin D deficiency. *Auris Nasus Larynx*. 2016;43(3):237-241. doi:10.1016/j.anl.2015.08.009

57. Tirelli G, Nicastro L, Gatto A, Tofanelli M. Repeated canalith repositioning procedure in BPPV: effects on recurrence and dizziness prevention. *Ame J Otol*. 2017;38(1):38-43. doi:10.1016/j.ajoto.2016.09.009

58. Yang CJ, Kim Y, Lee HS, Park HJ. Bone mineral density and serum 25-hydroxyvitamin D in patients with idiopathic benign paroxysmal positional vertigo. *J Vestib Res*. 2017;27(5-6):287-294. doi:10.3233/ves-170625

59. Chen XX, Jin ZG, Xu XR, Zhang Y, Wang CL. Risk factors for recurrence of benign paroxysmal positional vertigo in different age groups. *Med J Air Force*. 2018;34(2):123-126. doi:10.3969/j.issn.2095-3402.2018.02.015

60. Liu XW, Sun JW. [Risk factors analysis for recurrence of the idiopathic benign positional vertigo]. *Lin Chung Er Bi Yan Hou Jing Wai Ke Za Zhi*. 2018;32(15):1185-1187. doi: 10.13201/j.issn.1001-1781.2018.15.014

61. Luryi AL, Larouere MJ, Babu S, et al. Traumatic versus idiopathic benign paroxysmal positional vertigo: analysis of patient, treatment, and outcome characteristics. *Otolaryngol Head Neck Surg (United States)*. 2018;159(1):P142-P143. doi: 10.1177/0194599817885627f

62. Luryi AL, Lawrence J, Bojrab D, et al. Patient, disease, and outcome characteristics of benign paroxysmal positional vertigo with and without Meniere’s disease. *Acta Otolaryngol*. 2018;138(10):893-897. doi:10.1080/00016489.2018.1484566

63. Luryi AL, Lawrence J, Bojrab DL, et al. Recurrence in benign paroxysmal positional vertigo: a large, single-institution study. *Otol Neurotol*. 2018;39(5):622-627. doi:10.1097/mao.0000000000001800

64. Maslovcr S, Soldo SB, Sestak A, Milinkovic K, Rjgic-Namcinski J, Soldo A. 25 (OH) D3 levels, incidence and recurrence of different clinical forms of benign paroxysmal positional vertigo. *Braz J Otorhinolaryngol*. 2018;84(4):453-459. doi:10.1016/j.bjorl.2017.05.007

65. Pollak L, Huna-Baron R, Oshrov M, Roni M. In whom does horizontal canal BPPV recur? Ame J Otol. 2018;39(4):410-412. doi:10.1016/j.amjoto.2018.04.003

66. Qin Haiyan ZM, Cai H. Analysis of influencing factors for recurrence of manual paroxysmal positional vertigo. *J Clin Res*. 2018;35(6):1186-1188.

67. Tian YS, Wang SZ, Liu Y, Wang D, Guo L.R. [Clinical features of the recurrence of idiopathic benign paroxysmal positional vertigo]. *Lin Chung Er Bi Yan Hou Jing Wai Ke Za Zhi*. 2018;32(2):118-121. doi:10.13201/j.issn.1001-1781.2018.02.010

68. Wang Y, Xia F, Wang W, Hu W. Assessment of sleep quality in benign paroxysmal positional vertigo recurrence. *Int J Neurosci*. 2018;128(12):1143-1149. doi:10.1080/00207454.2018.1486835

69. Wei W, SayydZN, Ma X, Wang T, Dong Y. Presence of anxiety and depression symptoms affects the first time treatment efficacy and recurrence of benign paroxysmal positional vertigo. *Front Neurol*. 2018;9:178. doi:10.3389/fineru.2018.00178

70. Yeo SC, Ahn SK, Lee HJ, et al. Idiopathic benign paroxysmal positional vertigo in the elderly: a long-term follow-up study. *Aging Clin Exp Res*. 2018;30(2):153-159. doi:10.1007/s40520-017-0763-2
71. Chen G, Zhao X, Yu G, Jian H, Li Y, Xu G. Otolith dysfunction in recurrent benign paroxysmal positional vertigo after mild traumatic brain injury. Acta Oto-Laryngologica. 2019;139(1):18-21. doi:10.1080/00016489.2018.1562214

72. Li Yujuan I.P. Analysis of clinical characteristics of patients with benign paroxysmal positional vertigo of different genders. Neural Injury Function Recons. 2019;14(3):156-158. doi:10.16780/j.cnki.sjssgncj.2019.03.017

73. Martellucci S, Attanasio G, Ralli M, et al. Does cervical range of motion affect the outcomes of canalith repositioning procedures for posterior canal benign paroxysmal positional vertigo? Am J Otolaryngol. 2019;40(4):494-498. doi:10.1016/j.amjoto.2019.04.003

74. Rhim GI. Serum vitamin d and long-term outcomes of benign paroxysmal positional vertigo. Clin Exp Oto. 2019;12(3):273-278. doi:10.21053/ceo.2018.00381

75. Sayal NR, Cox EL, Foster N, Glober M, Farrugia M. Analysis of patients diagnosed with benign paroxysmal positional vertigo and the corresponding incidence and patterns of electric toothbrush use. Currus. 2019;11(9):E15. doi:10.7759/currus.5697

76. Sreenivas V, Sima NH, Philip S. The role of comorbidities in benign paroxysmal positional vertigo. Ear Nose Throat J. 2019;145561319878546. doi:10.1177/019459989950181675

77. Su-Jin Han CYK, Dae Bo S, Mee Hyun S. Analysis of risk factors for recurrence of benign paroxysmal positional vertigo: an 11-year nationwide population-based study. Korean J Otorhinolaryngol. 2019;62(1):15-22. doi:10.3342/kjorl-hns.2017.00899

78. Xiaozhong J. Clinical Features and Recurrent Risk Factors Analysis of 569 patients with Benign Paroxysmal Positional Vertigo. Jilin University; 2019;

79. Strupp M, Arbosov V. Acute vestibulopathy. Curr Opin Neurol. 2001;14(1):11-20. doi:10.1097/00005537-199501000-00011

80. Schuknecht HF. Cupulolithiasis. Arch Otol. 1969;90(6):765-778. doi:10.1001/archot.1969.00770030767020

81. Hall SF, Ruby RR, McClure JA. The mechanics of benign paroxysmal vertigo. J Otol. 1979;8(2):151-158.

82. Chau AT, Menant JC, Hubner PP, Lord SR, Migliaccio AA. Prevalence of vestibular disorder in older people who experience dizziness. Front Neurol. 2015;6:268. doi:10.3389/fneur.2015.00268

83. von Brevern M, Radtke A, Lezius F, et al. Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neuro Psychiatry. 2007;78(7):710-715. doi:10.1136/jnnp.2006.104020

84. Vibert D, Kompis M, Hauserl R. Benign paroxysmal positional vertigo in older women may be related to osteoporosis and osteopenia. Ann Otol Rhinol Laryngol. 2003;112(10):885-889. doi:10.1177/00034894031201010

85. Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13(5):763-773. doi:10.1359/jbmr.1998.13.5.763

86. Hughes I, Thalmann I, Thalmann R, Ornitz DM. Mixing model systems; using zebrafish and mouse inner ear mutants and other organ systems to unravel the mystery of otoconial development. Brain Res. 2006;1091(1):58-74. doi:10.1016/j.brainres.2006.01.074

87. Campos A, Crespo PV, Garcia JM, Sanchez-Quevedo MC, Ciges M. The crystalline pattern of calcium in different topographical regions of the otoconial membrane. an electron probe and spectroscopic diffraction study. Acta Otolaryngol. 1999;119(2):203-206. doi:10.1080/00016489950181675

88. Balatsouras DG, Koukoutsis G, Fassolis A, Moukos A, Apris A. Benign paroxysmal positional vertigo in the elderly: current insights. Clin Int Aging. 2018;13:2251-2266. doi:10.2147/CIA.S144134

89. Korres S, Balatsouras DG, Kaberos A, Economou C, Kandiloros D, Ferekidis E. Occurrence of semicircular canal involvement in benign paroxysmal positional vertigo. Otol Neurotol. 2002;23(6):926-932. doi:10.1097/019459989950181675

90. von Brevern M, Seelig T, Neuhauser H, Lempert T. Benign paroxysmal positional vertigo predominantly affects the right labyrinth. J Neurol Neurosurg Psychiatry. 2004;75(10):1487-1488. doi:10.1136/jnnp.2003.031500

91. Cohen HS, Kimball KT, Stewart MG. Benign paroxysmal positional vertigo and comorbid conditions. ORL. 2004;66(1):11-15. doi:10.1159/000077227

92. D’Silva LJ, Staeecker H, Lin J, et al. Retrospective data suggests that the higher prevalence of benign paroxysmal positional vertigo in individuals with type 2 diabetes is mediated by hypertension. J Vestib Res. 2016;25(5-6):233-239. doi:10.3233/VES-150563

93. Yoda S, Cureoglu S, Yildirim-Baylan M, et al. Association between type 1 diabetes mellitus and deposits in the semicircular canals. Otolaryngol Head Neck Surg. 2011;145(3):458-462. doi:10.1177/0194599811407610

94. Jauregui-Renaud K, Aranda-Moreno C, Herrera-Rangel A. Utricular hypofunction in patients with type 2 diabetes mellitus. Acta Otorhinolaryngol Ital. 2017;37(5):430-435. doi:10.14639/0392-100x-1243

95. Moriarty B, Rutka J, Hawke M. The incidence and distribution of cupular deposits in the labyrinth. Laryngoscope. 1992;102(1):56-59. doi:10.1289/0005537-199201000-00011

96. Lopez-Escamez JA, Gamiz MJ, Finana MG, Perez AF, Canet IS. Position in bed is associated with left or right location in benign paroxysmal positional vertigo of the posterior semicircular canal. Am J Otolaryngol. 2002;23(5):263-266. doi:10.1053/ajot.2002.124199

97. Wada M, Naganuma H, Tokumasu K, Hashimoto S, Ito A, Okamoto M. Arteriosclerotic changes as background factors in patients with peripheral vestibular disorders. Int Tinnitus J. 2000;124199

98. M. The crystalline pattern of calcium in different topographical regions of the otoconial membrane. an electron probe and spectroscopic diffraction study. Acta Otolaryngol. 1999;119(2):203-206. doi:10.1080/00016489950181675

99. Hemenway WG, Lindsay JR. Postural vertigo due to unilateral sudden partial loss of vestibular function. Ann Otol Rhinol Laryngol. 1956;65(3):692-706. doi:10.1177/000348945606500311
100. Yang X, Yang B, Wu M, et al. Association between serum uric acid levels and benign paroxysmal positional vertigo: a systematic review and meta-analysis of observational studies. *Front Neurol*. 2019;10:91. doi:10.3389/fneur.2019.00091

101. Celikbilek A, Gencer ZK, Saydam L, Zararsiz G, Tanik N, Ozkiris M. Serum uric acid levels correlate with benign paroxysmal positional vertigo. *Euro J Neurol*. 2014;21(1):79-85. doi:10.1111/ej.12248

102. Jeong SH, Choi SH, Kim JY, Koo JW, Kim HJ, Kim JS. Osteopenia and osteoporosis in idiopathic benign positional vertigo. *Neurology*. 2009;72(12):1069-1076. doi:10.1212/wnl.0b013e3181aa2e0

103. Mikulec AA, Kowalczyk KA, Pfitzinger ME, Harris DA, Jack-104. Jeong S-H, Kim J-S, Shin JW, et al. Decreased serum vitamin D in idiopathic benign positional vertigo. *J Neurol*. 2013;260(3):832-838. doi:10.1007/s00415-012-6712-2

105. Buki B, Ecker M, Junger H, Lundberg YW. Vitamin D deficiency and benign paroxysmal positioning vertigo. *Med Hypo*. 2013;80(2):201-204. doi:10.1016/j.mehy.2012.11.029

106. Saeed BMN, Omari A. Climatic variations and benign paroxysmal positional vertigo. *J Otol*. 2016;11(1):33-37. doi:10.1016/j.joto.2016.03.002

107. Vibert D, Sans A, Kompis M, et al. Ultrastructural changes in otocoria of osteoporotic rats. *Audio Neuro*. 2008;13(5):293-301. doi:10.1159/000124277

108. Yang CJ, Kim Y, Lee HS, Park HJ. Bone mineral density and benign paroxysmal positional vertigo. *Adv Otol Rhinol Laryngol*. 2009;118(9):670-676. doi:10.1177/000348940010001534

109. Korpon JR, Sabo RT, Coelho DH. Barometric pressure and the incidence of benign paroxysmal positional vertigo. *Am J Otolaryngol*. 2019;40(5):641-644. doi:10.1016/j.amjoto.2019.05.016

110. Karatas A, Acar Yuceant G, Yuce T, Haci C, Cebi IT, Salviz M. Association of benign paroxysmal positional vertigo with osteoporosis and vitamin d deficiency: a case controlled study. *Otol Neurotol*. 2017;38(9):1315-1318. doi:10.1097/mao.0000000000015134

111. Corroon JR, Sato G, Sekine K, Matsuda K, Takeda N. Effects of sleep position on time course in remission of positional vertigo in Meniere’s disease. *J Otolaryngol*. 2012;41(2):105-106. doi:10.1007/s12011-008-0150-z

112. Shim DB, Kim JH, Park KC, Song MH, Park HJ. Correlation between head-lying side during sleep and the affected side by benign paroxysmal positional vertigo involving the posterior or horizontal semicircular canal. *Laryngoscope*. 2012;122(4):873-876. doi:10.1002/lary.23180

113. Neri M, Frustaci A, Milic M, et al. A meta-analysis of biomarkers related to oxidative stress and nitric oxide pathway in migraine. *Cephalalgia*. 2015;35(10):931-937. doi:10.1177/033102414568888

114. Thomsen LL. Investigations into the role of nitric oxide and the large intracranial arteries in migraine headache. *Cephalalgia*. 1997;17(8):873-895. doi:10.1080/01480269719971708873

115. Tepper D. Migraine associated vertigo. *Headache*. 2015;55(10):1475-1476. doi:10.1111/head.12704

116. Evans RW, Ishiyama G. Migraine with transient unilateral hearing loss and tinnitus. *Headache*. 2009;49(5):756-758. doi:10.1111/j.1526-4610.2008.01075.x

117. Neri M, Frustaci A, Milic M, et al. Association between treated osteoporosis and vitamin d deficiency and idiopathic benign paroxysmal positional vertigo. *J Int Adv Otol*. 2016;12(1):101-105. doi:10.5152/iao.2015.1412

118. Ciancarelli I, Tozzi-Ciancarelli MG, Spacca G, Di Massimo C, Carolei A. Relationship between biofeedback and oxidative stress in patients with chronic migraine. *Cephalalgia*. 2007;27(10):1136-1141. doi:10.1111/j.1468-2982.2007.01398.x

119. Shimomura T, Kowa H, Nakano T, et al. Platelet superoxide dismutase in migraine and tension-type headache. *Cephalalgia*. 1994;14(3):215-218; discussion 181. doi:10.1046/j.1468-2982.1994.014003215.x

120. Tuncel D, Tolun FI, Gokce M, Imrek S, Ekerbicer H. Oxidative stress in migraine with and without aura. *Biol Trace Element Res*. 2008;126(1-3):92-97. doi:10.1007/s12011-008-0162-9

121. Ishiyama A, Jacobson KM, Baloh RW. Migraine and benign positional vertigo. *Ann Otol Rhinol Laryngol*. 2000;109(4):377-380. doi:10.1177/000348940010900407

122. Karlberg M, Hall K, Quickert N, Hinson J, Halmagyi GM. What inner ear diseases cause benign paroxysmal positional vertigo? *Acta Oto-Laryngologica*. 2000;120(3):380-385. doi:10.1080/00016480750000603

123. Katsarkas A, Kirkham TH. Paroxysmal positional vertigo—a study of 255 cases. *J Otolaryngol*. 1978;7(4):320-330.

124. Yetiser S. Co-existence of benign paroxysmal positional vertigo and Meniere’s syndrome. *J Int Adv Otol*. 2017;13(1):65-68. doi:10.5152/iao.2016.2906

125. Yamane H, Sunami K, Iguchi H, Sakamoto H, Imoto T, Rask-Andersen H. Assessment of Meniere’s disease from a radiological aspect - saccular otorrhea as a cause of Meniere’s disease? *Acta Oto-Laryngologica*. 2012;132(10):1054-1060. doi:10.3109/00016480750000603

126. Morita N, Cureoglu S, Nomiya S, et al. Potential cause of positional vertigo in Meniere’s disease. *Otol Neurotol*. 2009;30(7):956-960. doi:10.1097/MAO.0b013e3181b24368

127. Shim DB, Kim JH, Park KC, Song MH, Park HJ. Correlation between the head-lying side during sleep and the affected side by benign paroxysmal positional vertigo involving the posterior or horizontal semicircular canal. *Laryngoscope*. 2012;122(4):873-876. doi:10.1002/lary.23180

128. Sato G, Sekine K, Matsuda K, Takeda N. Effects of sleep position on time course in remission of positional vertigo in patients with benign paroxysmal positional vertigo. *Acta Oto-Laryngologica*. 2012;132(6):614-617. doi:10.3109/00016489.2012.655860
130. Dornhoffer JL, Colvin GB. Benign paroxysmal positional vertigo and canalith repositioning: clinical correlations. *Am J Otol*. 2000;21(2):230-233. doi:10.1016/s0196-0709(00)80014-9

131. Gross EM, Ress BD, Viirre ES, Nelson JR, Harris JP. Intractable benign paroxysmal positional vertigo in patients with Meniere’s disease. *Laryngoscope*. 2000;110(4):655-659. doi:10.1097/00005537-200004000-00022

132. Parnes LS, McClure JA. Free-floating endolymph particles: a new operative finding during posterior semicircular canal occlusion. *Laryngoscope*. 1992;102(9):988-992. doi:10.1288/00016489920180360

133. Motin M, Keren O, Gros Wasser Z, Gordon CR. Benign paroxysmal positional vertigo as the cause of dizziness in patients after severe traumatic brain injury: diagnosis and treatment. *Brain Injury*. 2005;19(9):693-697. doi:10.1080/02699005.2005.987010.

134. Dix MR, Hallpike CS. The pathology, symptomatology and diagnosis of certain common disorders of the vestibular system. *Ann Otol Rhinol Laryngol*. 1952;61(4):987-1016. doi:10.1177/003489452061000403

135. Katsarkas A. Benign paroxysmal positional vertigo (BPPV): idiopathic versus post-traumatic. *Acta Otolaryngol*. 1999;119(7):745-749. doi:10.1080/00016489950180360

136. Riga M, Bibas A, Xenellis J, Korres S. Inner ear disease and benign paroxysmal positional vertigo: a critical review of incidence, clinical characteristics, and management. *Int J Otolaryngol*. 2011;709469. doi:10.1155/2011/709469

137. Hong SM, Park DC, Yeo SG, Cha CI. Vestibular evoked myogenic potentials in patients with benign paroxysmal positional vertigo involving each semicircular canal. *Am J Otolaryngol*. 2008;29(3):184-187. doi:10.1016/j.amjoto.2007.07.004

138. Yang WS, Kim SH, Lee JD, Lee WS. Clinical significance of vestibular evoked myogenic potentials in benign paroxysmal positional vertigo. *Otol Neurotol*. 2008;29(8):1162-1166. doi:10.1097/MAO.0b013e31818a0881

139. von Brevern M, Schmidt T, Schonfeld U, Lempert T, Clarke AH. Utricular dysfunction in patients with benign paroxysmal positional vertigo. *Otol Neurotol*. 2006;27(1):92-96. doi:10.1097/10. mao.0b013e3182275b95

140. Han DG, Kim DJ. The evolutionary hypothesis of benign paroxysmal positional vertigo. *Med Hypo*. 2019;134:109445. doi:10.1016/j.mehy.2019.109445